1208912-84-8
Chemical Structure
Patiromer
- CAS No.: 1208912-84-8
- Formula:C28H48CaFO2+
- Molecular Weight:N/A
SMILES: CCC(C([O-])=O)(F)CC(C1=CC=CC=C1)CC(CCCCC(C)CC)C.CC(CC)C.[Ca+2].[p].[p].[n].[m].[n].[1/2]
Biological Activity: Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Patiromer | 95.0% | Patiromer is an orally active, selective and non-absorbable intestinal potassium (K+) polymer binder that reversibly binds potassium ions in exchange for calcium (Ca2+). Patiromer can rapidly and continuously reduce serum potassium levels, maintain a normal blood potassium state, and reduce serum aldosterone levels. Patiromer also increases fecal potassium excretion. Patiromer is mainly used in the study of hyperkalemia associated with diseases such as chronic kidney disease, diabetes, and heart failure, and is particularly suitable for improving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Weir MR, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21. [Content Brief]
- [2]. Iyer SPN, et al. Pharmacodynamic effects of the K+ binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats. Physiol Rep. 2020 Sep;8(18):e14572. [Content Brief]
- [3]. Colbert GB, et al. Patiromer for the treatment of hyperkalemia. Expert Rev Clin Pharmacol. 2020 Jun;13(6):563-570. [Content Brief]
Keywords
